Small-Molecule Antagonists of p53-MDM2 Binding: Research Tools and Potential Therapeutics

 Abstract

p53 regulates a key pathway which protects normal tissues from tumor development that may result from diverse forms of stress. In the absence of stress, growth suppressive and proapoptotic activity of p53 is inhibited by MDM2 which binds p53 and negatively regulates its activity and stability. MDM2 antagonists could activate p53 and may offer a novel therapeutic approach to cancer. Recently, we identified the first potent and selective low molecular weight inhibitors of MDM2-p53 binding, the Nutlins. These molecules activate the p53 pathway and suppress tumor growth in vitro and in vivo. Nutlins represent valuable new tools for studying the p53 pathway and its defects in cancer. Their potent activity against osteosarcoma xenogrfts suggests that MDM2 antagonists may have a clinical utility in the treatment of tumors with wild-type p53.

Full Text Options
Article
Metrics
 Share
 Info
Pages
417 - 419
doi
10.4161/cc.3.4.801
Type
Extra Views
 Metrics
 Cite This Article
 Permissions
 Permissions
 Reprints
Small-Molecule Antagonists of p53-MDM2 Binding: Research Tools and Potential Therapeutics